Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


Purpose:

RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as MDX-010 and GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with MDX-010 and GM-CSF may be an effective treatment for prostate cancer. PURPOSE: This phase I trial is studying the side effects and best dose of MDX-010 when given together with vaccine therapy and GM-CSF in treating patients with metastatic prostate cancer.


Study summary:

OBJECTIVES: Primary - Determine the maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) when given with sargramostim (GM-CSF) and vaccine therapy comprising vaccinia-PSA-TRICOM vaccine and fowlpox-PSA-TRICOM vaccine in patients with androgen-independent metastatic prostate cancer. - Determine the safety and tolerability of this regimen in these patients. Secondary - Determine immunologic response, as measured by an increase in prostate-specific antigen (PSA) specific T-cells by ELISPOT assay, in HLA-A2-positive patients treated with this regimen. - Determine the clinical response, as measured by RECIST and PSA consensus criteria, in patients treated with this regimen. OUTLINE: This is an open-label, dose-escalation study of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010). Patients receive a priming vaccination with vaccinia-PSA-TRICOM vaccine subcutaneously (SC) on day 1 and sargramostim (GM-CSF) SC on days 1-4. Patients then receive booster vaccinations with fowlpox-PSA-TRICOM vaccine SC and MDX-010 IV over 90 minutes on days 15, 43, 71, 99, 127, and 155. Patients also receive GM-CSF SC on days 15-18, 43-46, 71-74, 99-102, 127-130, and 155-158. Patients without disease progression after day 155 may continue to receive fowlpox-PSA-TRICOM vaccine and GM-CSF every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of MDX-010 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. After completion of study treatment, patients are followed at 4 weeks and then annually for 15 years. PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 2-3 years.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed prostate cancer - Metastatic disease - Androgen-independent disease - No bone pain requiring narcotics - No brain metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - At least 6 months Hematopoietic - Granulocyte count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 - Lymphocyte count ≥ 500/mm^3 - Hemoglobin ≥ 9 g/dL Hepatic - AST and ALT ≤ 2.5 times upper limit of normal - Bilirubin ≤ 1.5 mg/dL (total bilirubin ≤ 3.0 mg/dL for patients with Gilbert's syndrome) - Hepatitis B negative - Hepatitis C negative Renal - Creatinine clearance ≥ 60 mL/min - No proteinuria ≥ grade 2 (unless the cause is determined to be nonrenal) Cardiovascular - No history of congestive heart failure OR objective evidence of congestive heart failure by physical exam or imaging - No New York Heart Association class II-IV cardiac disease Pulmonary - No pulmonary disease with fatigue or dyspnea during ordinary physical activity Gastrointestinal - No inflammatory bowel disease - No Crohn's disease - No ulcerative colitis - No active diverticulitis Immunologic - HIV negative - No history of allergy or untoward reaction to prior vaccination with vaccinia virus or to any component of the vaccinia regimen - No serious hypersensitivity reaction to egg products - No autoimmune disease that requires treatment, including any of the following: - Addison's disease - Hashimoto's thyroiditis - Systemic lupus erythematosus - Sjögren's syndrome - Scleroderma - Goodpasture's syndrome - Active Graves disease - Autoimmune hemolytic anemia - Ulcerative and hemorrhagic colitis - Endocrine disorders (e.g., thyroiditis, hyperthyroidism, hypothyroidism, autoimmune hypophysitis/hypopituitarism, or adrenal insufficiency) - Sarcoid granuloma - Myasthenia gravis - Polymyositis - Guillain-Barre syndrome - History of autoimmunity allowed provided it has not required systemic immunosuppressive therapy OR does not threaten vital organ function, including the CNS, heart, lungs, kidneys, skin, and gastrointestinal tract - No history of multiple sclerosis - No immunodeficiency or immunosuppression (by disease or therapy) - No history of or active eczema or other eczematoid skin disorder - No other acute, chronic, or exfoliative skin condition, including any of the following: - Atopic dermatitis - Burns - Impetigo - Varicella zoster - Severe acne - Other open rashes or wounds Other - Fertile patients must use effective contraception during and for ≥ 4 months after completion of study treatment - No history of seizures - No history of encephalitis - No other active malignancy within the past 12 months except nonmelanoma skin cancer or carcinoma in situ of the bladder - No life-threatening illness - Able to avoid close household contact with the following individuals for ≥ 3 weeks after vaccination: - Individuals with prior or active eczema or other eczematoid skin disorder - Individuals with other acute, chronic, or exfoliative skin condition, including any of the following: - Atopic dermatitis - Burns - Impetigo - Varicella zoster - Severe acne - Other open rashes or wounds - Children 3 years of age or younger - Pregnant or nursing women - Immunodeficient or immunosuppressed individuals (by disease or therapy), including HIV-infected individuals - No other serious medical illness that requires treatment and would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy - Prior vaccinia immunization allowed - No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) - No other concurrent anticancer immunotherapy Chemotherapy - See Disease Characteristics - No prior chemotherapy - No concurrent chemotherapy Endocrine therapy - More than 2 weeks since prior and no concurrent systemic or topical steroids, including steroid eye drops - Nasal or inhaled steroids allowed - Concurrent gonadotropin-releasing hormone agonist or antagonist therapy required for patients who have not undergone prior bilateral surgical orchiectomy - No concurrent anticancer systemic glucocorticoids - Concurrent replacement glucosteroids for patients with pituitary insufficiency allowed - Concurrent steroids for therapy-induced autoimmunity allowed Radiotherapy - No concurrent anticancer radiotherapy Surgery - See Endocrine therapy - Recovered from prior surgery - No prior splenectomy - No concurrent major surgery for treatment of cancer Other - Recovered from prior therapy


NCT ID:

NCT00124670


Primary Contact:

Principal Investigator
James L. Gulley, MD, PhD, FACP
National Cancer Institute (NCI)


Backup Contact:

N/A


Location Contact:

Bethesda, Maryland 20892
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.